A Randomized Trial of Tenecteplase versus Alteplase for Acute Ischemic Stroke

Parsons, Mark; J. Spratt, Neil; Bivard, Andrew; Campbell, Bruce; Mun Chung, Kong; Miteff, Ferdinand; O’Brien, Bill; Bladin, Christopher; McElduff, Patrick; Allen, Chris; A. Bateman, Grant; A. Donnan, Geoffrey; M. Davis, Stephen; Levi, Christopher

doi:10.1056/nejmoa1109842

Public

A Randomized Trial of Tenecteplase versus Alteplase for Acute Ischemic Stroke

Published in New England Journal of Medicine • Mar 22, 2012

Authors:

Mark Parsons

Neil J. Spratt

Andrew Bivard

Abstract

BACKGROUND: Intravenous alteplase is the only approved treatment for acute ischemic stroke. Tenecteplase, a genetically engineered mutant tissue plasminogen activator, is an alternative thrombolytic agent. METHODS: In this phase 2B trial, we randomly assigned 75 patients to receive alteplase (0.9 mg...

Subject

Medicine

Tenecteplase

Randomized controlled trial

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!